Drugs / TAK-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04530123 | Jun 2022 → Dec 2025 | celiac disease | Takeda | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04530123 ↗ |
| Route | Intravenous | “TAK 101 intravenous infusion” NCT04530123 ↗ |